{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T04:05:22Z","timestamp":1794197122177,"version":"4.8.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1038\/s41591-026-04305-w","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T09:03:29Z","timestamp":1775207009000},"page":"1223-1232","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Target product profiles for treatments to delay or prevent symptomatic Alzheimer\u2019s disease"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8944-4158","authenticated-orcid":false,"given":"Jeffrey L.","family":"Cummings","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9602-0406","authenticated-orcid":false,"given":"Michael G.","family":"Agadjanyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2179-2436","authenticated-orcid":false,"given":"Lawrence","family":"Corey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachelle","family":"Doody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Hendrix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4666-9132","authenticated-orcid":false,"given":"Soeren","family":"Mattke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8885-7724","authenticated-orcid":false,"given":"Niklas","family":"Mattsson-Carlgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6764-3866","authenticated-orcid":false,"given":"Eric","family":"McDade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5657-1994","authenticated-orcid":false,"given":"Joseph P.","family":"Menetski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3765-6287","authenticated-orcid":false,"given":"Richard C.","family":"Mohs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine A.","family":"Partrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1580-5245","authenticated-orcid":false,"given":"Nikolai","family":"Petrovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8846-9767","authenticated-orcid":false,"given":"Dennis J.","family":"Selkoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1535-6133","authenticated-orcid":false,"given":"Reisa A.","family":"Sperling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Tiede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Vradenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,3]]},"reference":[{"key":"4305_CR1","unstructured":"World Health Organization. Global status report on the public health response to dementia. https:\/\/www.who.int\/publications\/i\/item\/9789240033245 (2021)."},{"key":"4305_CR2","doi-asserted-by":"crossref","unstructured":"2024 Alzheimer\u2019s disease facts and figures. Alzheimers Dement. 20, 3708\u20133821 (2024).","DOI":"10.1002\/alz.13809"},{"key":"4305_CR3","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/S2468-2667(21)00249-8","volume":"7","author":"E Nichols","year":"2022","unstructured":"Nichols, E. et al. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health 7, e105\u2013e125 (2022).","journal-title":"Lancet Public Health"},{"key":"4305_CR4","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/alz.12694","volume":"19","author":"A Gustavsson","year":"2023","unstructured":"Gustavsson, A. et al. Global estimates on the number of persons across the Alzheimer\u2019s disease continuum. Alzheimers Dement. 19, 658\u2013670 (2023).","journal-title":"Alzheimers Dement."},{"key":"4305_CR5","doi-asserted-by":"publisher","first-page":"729","DOI":"10.7326\/M15-0381","volume":"163","author":"AS Kelley","year":"2015","unstructured":"Kelley, A. S., McGarry, K., Gorges, R. & Skinner, J. S. The burden of health care costs for patients with dementia in the last 5 years of life. Ann. Intern. Med. 163, 729\u2013736 (2015).","journal-title":"Ann. Intern. Med."},{"key":"4305_CR6","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.nurpra.2022.01.003","volume":"18","author":"KLP Settje","year":"2022","unstructured":"Settje, K. L. P., Yap, T. L., Chapman, S., Brooks, K. & Sabol, V. K. Implementation of nurse-led cognitive screening during Medicare annual wellness visits. Nurse Pract. 18, 516\u2013521 (2022).","journal-title":"Nurse Pract."},{"key":"4305_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101580","volume":"51","author":"A Nandi","year":"2022","unstructured":"Nandi, A. et al. Global and regional projections of the economic burden of Alzheimer\u2019s disease and related dementias from 2019 to 2050: a value of statistical life approach. EClinicalMedicine 51, 101580 (2022).","journal-title":"EClinicalMedicine"},{"key":"4305_CR8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/joim.20098","volume":"298","author":"NR Fowler","year":"2025","unstructured":"Fowler, N. R. et al. Implementing early detection of cognitive impairment in primary care to improve care for older adults. J. Intern. Med. 298, 31\u201345 (2025).","journal-title":"J. Intern. Med."},{"key":"4305_CR9","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S0140-6736(24)01296-0","volume":"404","author":"G Livingston","year":"2024","unstructured":"Livingston, G. et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet 404, 572\u2013628 (2024).","journal-title":"Lancet"},{"key":"4305_CR10","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1001\/jama.2025.12923","volume":"334","author":"LD Baker","year":"2025","unstructured":"Baker, L. D. et al. Structured vs self-guided multidomain lifestyle interventions for global cognitive function: the US POINTER randomized clinical trial. JAMA 334, 681\u2013691 (2025).","journal-title":"JAMA"},{"key":"4305_CR11","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1177\/1559827618812395","volume":"13","author":"JM Rippe","year":"2019","unstructured":"Rippe, J. M. Lifestyle strategies for risk factor reduction, prevention, and treatment of cardiovascular disease. Am. J. Lifestyle Med. 13, 204\u2013212 (2019).","journal-title":"Am. J. Lifestyle Med."},{"key":"4305_CR12","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack Jr.","year":"2024","unstructured":"Jack, C. R. Jr. et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup. Alzheimers Dement. 20, 5143\u20135169 (2024).","journal-title":"Alzheimers Dement."},{"key":"4305_CR13","unstructured":"US Food and Drug Administration. Early Alzheimer\u2019s disease: developing drugs for treatment. Guidance for industry. FDA https:\/\/www.fda.gov\/media\/110903\/download (2024)."},{"key":"4305_CR14","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr.","year":"2018","unstructured":"Jack, C. R. Jr. et al. NIA-AA Research Framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 14, 535\u2013562 (2018).","journal-title":"Alzheimers Dement."},{"key":"4305_CR15","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/s41591-021-01382-x","volume":"27","author":"O Hansson","year":"2021","unstructured":"Hansson, O. Biomarkers for neurodegenerative diseases. Nat. Med. 27, 954\u2013963 (2021).","journal-title":"Nat. Med."},{"key":"4305_CR16","doi-asserted-by":"publisher","first-page":"303","DOI":"10.14283\/jpad.2024.23","volume":"11","author":"S Mattke","year":"2024","unstructured":"Mattke, S. et al. Health economic considerations in the deployment of an Alzheimer\u2019s prevention therapy. J. Prev. Alzheimer. Dis. 11, 303\u2013309 (2024).","journal-title":"J. Prev. Alzheimer. Dis."},{"key":"4305_CR17","unstructured":"Eli Lilly and Company. Kisunla. Prescribing information. https:\/\/uspl.lilly.com\/kisunla\/kisunla.html#pi (2024)."},{"key":"4305_CR18","unstructured":"Eisai & Biogen. Leqembi. Prescribing information. https:\/\/www.leqembi.com\/-\/media\/Files\/Leqembi\/Prescribing-Information.pdf (2023)."},{"key":"4305_CR19","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/s43587-024-00611-5","volume":"4","author":"DJ Selkoe","year":"2024","unstructured":"Selkoe, D. J. The advent of Alzheimer treatments will change the trajectory of human aging. Nat. Aging 4, 453\u2013463 (2024).","journal-title":"Nat. Aging"},{"key":"4305_CR20","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/S1474-4422(25)00483-1","volume":"25","author":"EM Reiman","year":"2026","unstructured":"Reiman, E. M. et al. A path to preventing cognitive impairment due to Alzheimer\u2019s disease: initiatives beginning in the USA. Lancet Neurol. 25, 268\u2013278 (2026).","journal-title":"Lancet Neurol."},{"key":"4305_CR21","unstructured":"Alzheimer\u2019s Prevention Accelerator. Accelerating alzheimer\u2019s prevention: a global imperative. Squarespace https:\/\/static1.squarespace.com\/static\/6729302c70a0c23130595fe3\/t\/678a90752731c5708b1461ce\/1737134201069\/Alzheimer%27s+Prevention+Accelerator+-+Final+2024+Report.pdf (2024)."},{"key":"4305_CR22","volume":"11","author":"JL Cummings","year":"2025","unstructured":"Cummings, J. L. et al. Alzheimer\u2019s disease drug development pipeline: 2025. Alzheimers Dement. 11, e70098 (2025).","journal-title":"Alzheimers Dement."},{"key":"4305_CR23","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jalz.2016.07.005","volume":"13","author":"RJ Bateman","year":"2017","unstructured":"Bateman, R. J. et al. The DIAN-TU Next Generation Alzheimer\u2019s prevention trial: adaptive design and disease progression model. Alzheimers Dement. 13, 8\u201319 (2017).","journal-title":"Alzheimers Dement."},{"key":"4305_CR24","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1002\/alz.12748","volume":"19","author":"MS Rafii","year":"2023","unstructured":"Rafii, M. S. et al. The AHEAD 3-45 study: design of a prevention trial for Alzheimer\u2019s disease. Alzheimers Dement. 19, 1227\u20131233 (2023).","journal-title":"Alzheimers Dement."},{"key":"4305_CR25","unstructured":"US National Library of Medicine. A donanemab (LY3002813) study in participants with preclinical Alzheimer\u2019s disease (TRAILBLAZER-ALZ 3). ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05026866 (2026)."},{"key":"4305_CR26","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/S1474-4422(25)00024-9","volume":"24","author":"RJ Bateman","year":"2025","unstructured":"Bateman, R. J. et al. Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer\u2019s disease: an open-label extension of the phase 2\/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial. Lancet Neurol. 24, 316\u2013330 (2025).","journal-title":"Lancet Neurol."},{"key":"4305_CR27","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/S1474-4422(23)00508-2","volume":"23","author":"EM Reiman","year":"2024","unstructured":"Reiman, E. M., Cummings, J. L., Langbaum, J. B., Mattke, S. & Alexander, R. C. A chance to prevent Alzheimer\u2019s disease sooner than you think. Lancet Neurol. 23, 144\u2013145 (2024).","journal-title":"Lancet Neurol."},{"key":"4305_CR28","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1056\/NEJMp2027405","volume":"383","author":"M Slaoui","year":"2020","unstructured":"Slaoui, M. & Hepburn, M. Developing safe and effective COVID vaccines - Operation Warp Speed\u2019s strategy and approach. N. Engl. J. Med. 383, 1701\u20131703 (2020).","journal-title":"N. Engl. J. Med."},{"key":"4305_CR29","unstructured":"US Department of Health and Human Services. From the factory to the frontlines: the Operation Warp Speed strategy for distributing a COVID-19 vaccine. HHS https:\/\/www.hhs.gov\/sites\/default\/files\/strategy-for-distributing-covid-19-vaccine.pdf"},{"key":"4305_CR30","unstructured":"World Health Organization. WHO target product profiles for COVID-19 vaccines. Revised April 2022. WHO https:\/\/cdn.who.int\/media\/docs\/default-source\/blue-print\/tpp-6apr-2022-final.pdf?sfvrsn=4f8cede5_4&download=true"},{"key":"4305_CR31","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41573-024-01102-3","volume":"24","author":"JF Demarest","year":"2025","unstructured":"Demarest, J. F. et al. Antiviral target compound profile for pandemic preparedness. Nat. Rev. Drug Discov. 24, 151\u2013152 (2025).","journal-title":"Nat. Rev. Drug Discov."},{"key":"4305_CR32","unstructured":"European Medicines Agency. Guideline on the clinical investigation of medicines for the treatment of Alzheimer\u2019s disease. EMA https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-clinical-investigation-medicines-treatment-alzheimers-disease-revision-2_en.pdf (2018)."},{"key":"4305_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14342","volume":"21","author":"P Aisen","year":"2025","unstructured":"Aisen, P. et al. The case for regulatory approval of amyloid-lowering immunotherapies in Alzheimer\u2019s disease based on clearcut biomarker evidence. Alzheimers Dement. 21, e14342 (2025).","journal-title":"Alzheimers Dement."},{"key":"4305_CR34","doi-asserted-by":"publisher","unstructured":"Petersen, K. K. et al. Predicting onset of symptomatic Alzheimer\u2019s disease with plasma p-tau217 clocks. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-026-04206-y (2026).","DOI":"10.1038\/s41591-026-04206-y"},{"key":"4305_CR35","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s40120-023-00445-0","volume":"12","author":"B Hauber","year":"2023","unstructured":"Hauber, B. et al. Assessing what matters to people affected by Alzheimer\u2019s disease: a quantitative analysis. Neurol. Ther. 12, 505\u2013527 (2023).","journal-title":"Neurol. Ther."},{"key":"4305_CR36","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13195-020-00659-6","volume":"12","author":"DB DiBenedetti","year":"2020","unstructured":"DiBenedetti, D. B. et al. Assessing what matters most to patients with or at risk for Alzheimer\u2019s and care partners: a qualitative study evaluating symptoms, impacts, and outcomes. Alzheimers Res. Ther. 12, 90 (2020).","journal-title":"Alzheimers Res. Ther."},{"key":"4305_CR37","first-page":"231","volume":"11","author":"C Tochel","year":"2019","unstructured":"Tochel, C. et al. What outcomes are important to patients with mild cognitive impairment or Alzheimer\u2019s disease, their caregivers, and health-care professionals? A systematic review. Alzheimers Dement. 11, 231\u2013247 (2019).","journal-title":"Alzheimers Dement."},{"key":"4305_CR38","first-page":"653","volume":"24","author":"B Reisberg","year":"1988","unstructured":"Reisberg, B. Functional assessment staging (FAST). Psychopharmacol. Bull. 24, 653\u2013659 (1988).","journal-title":"Psychopharmacol. Bull."},{"key":"4305_CR39","doi-asserted-by":"publisher","first-page":"855","DOI":"10.3233\/JAD-170903","volume":"62","author":"D Wang","year":"2018","unstructured":"Wang, D. et al. Longitudinal modeling of functional decline associated with pathologic Alzheimer\u2019s disease in older persons without cognitive impairment. J. Alzheimer. Dis. 62, 855\u2013865 (2018).","journal-title":"J. Alzheimer. Dis."},{"key":"4305_CR40","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13195-021-00834-3","volume":"13","author":"Y Guo","year":"2021","unstructured":"Guo, Y. et al. Characterization of Alzheimer\u2019s tau biomarker discordance using plasma, CSF, and PET. Alzheimers Res. Ther. 13, 93 (2021).","journal-title":"Alzheimers Res. Ther."},{"key":"4305_CR41","doi-asserted-by":"publisher","first-page":"507","DOI":"10.14283\/jpad.2022.41","volume":"9","author":"S Cohen","year":"2022","unstructured":"Cohen, S., Cummings, J., Knox, S., Potashman, M. & Harrison, J. Clinical trial endpoints and their clinical meaningfulness in early stages of Alzheimer\u2019s disease. J. Prev. Alzheimers Dis. 9, 507\u2013522 (2022).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"4305_CR42","first-page":"109","volume":"4","author":"J Cummings","year":"2017","unstructured":"Cummings, J. & Fox, N. Defining disease modifying therapy for Alzheimer\u2019s disease. J. Prev. Alzheimers Dis. 4, 109\u2013115 (2017).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"4305_CR43","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14425","volume":"21","author":"A Elhage","year":"2025","unstructured":"Elhage, A. et al. Defining benefit: clinically and biologically meaningful outcomes in the next-generation Alzheimer\u2019s disease clinical care pathway. Alzheimers Dement. 21, e14425 (2025).","journal-title":"Alzheimers Dement."},{"key":"4305_CR44","unstructured":"Eli Lilly. Lilly\u2019s Kisunla (donanemab-azbt) showed growing benefit over three years in early symptomatic Alzheimer\u2019s disease. https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-kisunla-donanemab-azbt-showed-growing-benefit-over-three (30 July 2025)."},{"key":"4305_CR45","doi-asserted-by":"publisher","first-page":"6374","DOI":"10.1002\/alz.14134","volume":"20","author":"LL Raket","year":"2024","unstructured":"Raket, L. L., Cummings, J., Moscoso, A., Villain, N. & Sch\u00f6ll, M. Scenarios for the long-term efficacy of amyloid-targeting therapies in the context of the natural history of Alzheimer\u2019s disease. Alzheimers Dement. 20, 6374\u20136383 (2024).","journal-title":"Alzheimers Dement."},{"key":"4305_CR46","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer, M. et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N. Engl. J. Med. 383, 1413\u20131424 (2020).","journal-title":"N. Engl. J. Med."},{"key":"4305_CR47","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1093\/ndt\/gfaa234","volume":"35","author":"DC Wheeler","year":"2020","unstructured":"Wheeler, D. C. et al. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. Nephrol. Dial. Transplant. 35, 1700\u20131711 (2020).","journal-title":"Nephrol. Dial. Transplant."},{"key":"4305_CR48","doi-asserted-by":"publisher","first-page":"373","DOI":"10.31083\/j.rcm2412373","volume":"24","author":"C Yang","year":"2023","unstructured":"Yang, C., Wu, Y. J., Qian, J. & Li, J. J. Landscape of statin as a cornerstone in atherosclerotic cardiovascular disease. Rev. Cardiovasc. Med. 24, 373 (2023).","journal-title":"Rev. Cardiovasc. Med."},{"key":"4305_CR49","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims, J. R. et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330, 512\u2013527 (2023).","journal-title":"JAMA"},{"key":"4305_CR50","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck, C. H. et al. Lecanemab in early Alzheimer\u2019s disease. N. Engl. J. Med. 388, 9\u201321 (2023).","journal-title":"N. Engl. J. Med."},{"key":"4305_CR51","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14283\/jpad.2022.30","volume":"9","author":"S Budd Haeberlein","year":"2022","unstructured":"Budd Haeberlein, S. et al. Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease. J. Prev. Alzheimer. Dis. 9, 197\u2013210 (2022).","journal-title":"J. Prev. Alzheimer. Dis."},{"key":"4305_CR52","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CHV Dyck","year":"2023","unstructured":"Dyck, C. H. V. et al. Lecanemab in early Alzheimer\u2019s disease. N. Engl. J. Med. 388, 9\u201321 (2023).","journal-title":"N. Engl. J. Med."},{"key":"4305_CR53","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1056\/NEJMoa2305032","volume":"389","author":"RA Sperling","year":"2023","unstructured":"Sperling, R. A. et al. Trial of solanezumab in preclinical Alzheimer\u2019s disease. N. Engl. J. Med. 389, 1096\u20131107 (2023).","journal-title":"N. Engl. J. Med."},{"key":"4305_CR54","doi-asserted-by":"publisher","first-page":"595","DOI":"10.14283\/jpad.2023.50","volume":"10","author":"SP Dickson","year":"2023","unstructured":"Dickson, S. P. et al. \u2018Time Saved\u2019 as a demonstration of clinical meaningfulness and illustrated using the donanemab TRAILBLAZER-ALZ study findings. J. Prev. Alzheimer. Dis. 10, 595\u2013599 (2023).","journal-title":"J. Prev. Alzheimer. Dis."},{"key":"4305_CR55","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s40120-022-00350-y","volume":"11","author":"AA Tahami Monfared","year":"2022","unstructured":"Tahami Monfared, A. A., Tafazzoli, A., Ye, W., Chavan, A. & Zhang, Q. Long-term health outcomes of lecanemab in patients with early Alzheimer\u2019s disease using simulation modeling. Neurol. Ther. 11, 863\u2013880 (2022).","journal-title":"Neurol. Ther."},{"key":"4305_CR56","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s40120-023-00473-w","volume":"12","author":"AA Tahami Monfared","year":"2023","unstructured":"Tahami Monfared, A. A. et al. A path to improved Alzheimer\u2019s care: simulating long-term health outcomes of lecanemab in early Alzheimer\u2019s disease from the CLARITY AD trial. Neurol. Ther. 12, 863\u2013881 (2023).","journal-title":"Neurol. Ther."},{"key":"4305_CR57","doi-asserted-by":"publisher","first-page":"529","DOI":"10.14283\/jpad.2024.64","volume":"11","author":"SP Dickson","year":"2024","unstructured":"Dickson, S. P. et al. \u201cTime Saved\u2019 calculations to improve decision-making in progressive disease studies. J. Prev. Alzheimer. Dis. 11, 529\u2013536 (2024).","journal-title":"J. Prev. Alzheimer. Dis."},{"key":"4305_CR58","volume":"11","author":"K Lanctot","year":"2025","unstructured":"Lanctot, K. et al. Measuring time saved in Alzheimer\u2019s disease: what is a meaningful slowing of progression?. Alzheimers Dement. 11, e70081 (2025).","journal-title":"Alzheimers Dement."},{"key":"4305_CR59","volume":"7","author":"A Mank","year":"2021","unstructured":"Mank, A. et al. Identifying relevant outcomes in the progression of Alzheimer\u2019s disease; what do patients and care partners want to know about prognosis?. Alzheimers Dement. 7, e12189 (2021).","journal-title":"Alzheimers Dement."},{"key":"4305_CR60","doi-asserted-by":"publisher","DOI":"10.1002\/alz.082852","volume":"19","author":"BA Willis","year":"2023","unstructured":"Willis, B. A., Penner, N., Rawal, S., Aluri, J. & Reyderman, L. Subcutaneous (SC) lecanemab is predicted to achieve comparable efficacy and improved safety compared to lecanemab IV in early Alzheimer\u2019s disease (AD). Alzheimers Dement. 19, e082852 (2023).","journal-title":"Alzheimers Dement."},{"key":"4305_CR61","unstructured":"US National Library of Medicine. A study of remternetug (LY3372993) in participants with Alzheimer\u2019s disease (TRAILRUNNER-ALZ 1). ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/study\/NCT05463731 (2025)."},{"key":"4305_CR62","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13024-021-00467-y","volume":"16","author":"E McDade","year":"2021","unstructured":"McDade, E., Llibre-Guerra, J. J., Holtzman, D. M., Morris, J. C. & Bateman, R. J. The informed road map to prevention of Alzheimer disease: a call to arms. Mol. Neurodegener. 16, 49 (2021).","journal-title":"Mol. Neurodegener."},{"key":"4305_CR63","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1016\/j.neuron.2023.05.017","volume":"111","author":"H Hampel","year":"2023","unstructured":"Hampel, H. et al. Blood-based biomarkers for Alzheimer\u2019s disease: Current state and future use in a transformed global healthcare landscape. Neuron 111, 2781\u20132799 (2023).","journal-title":"Neuron"},{"key":"4305_CR64","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1002\/alz.12756","volume":"18","author":"O Hansson","year":"2022","unstructured":"Hansson, O. et al. The Alzheimer\u2019s Association appropriate use recommendations for blood biomarkers in Alzheimer\u2019s disease. Alzheimers Dement. 18, 2669\u20132686 (2022).","journal-title":"Alzheimers Dement."},{"key":"4305_CR65","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/s43587-023-00400-6","volume":"3","author":"SE Schindler","year":"2023","unstructured":"Schindler, S. E. & Atri, A. The role of cerebrospinal fluid and other biomarker modalities in the Alzheimer\u2019s disease diagnostic revolution. Nat. Aging 3, 460\u2013462 (2023).","journal-title":"Nat. Aging"},{"key":"4305_CR66","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/s41582-024-00977-5","volume":"20","author":"SE Schindler","year":"2024","unstructured":"Schindler, S. E. et al. Acceptable performance of blood biomarker tests of amyloid pathology \u2014 recommendations from the Global CEO Initiative on Alzheimer\u2019s disease. Nat. Rev. Neurol. 20, 426\u2013439 (2024).","journal-title":"Nat. Rev. Neurol."},{"key":"4305_CR67","doi-asserted-by":"crossref","unstructured":"Mielke, M. M. et al. Recommendations for clinical implementation of blood-based biomarkers for Alzheimer\u2019s disease. Alzheimers Dement. 20, 8216\u20138224 (2024).","DOI":"10.1002\/alz.088356"},{"key":"4305_CR68","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70535","volume":"21","author":"S Palmqvist","year":"2025","unstructured":"Palmqvist, S. et al. Alzheimer\u2019s Association Clinical Practice Guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer\u2019s disease within specialized care settings. Alzheimers Dement. 21, e70535 (2025).","journal-title":"Alzheimers Dement."},{"key":"4305_CR69","unstructured":"US National Library of Medicine. Dominantly inherited alzheimer network trial: an opportunity to prevent dementia. A study of potential disease modifying treatments in individuals at risk for or with a type of early onset Alzheimer\u2019s disease caused by a genetic mutation. Master Protocol DIAN-TU-001 (DIAN-TU). ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT01760005 (2026)."},{"key":"4305_CR70","unstructured":"US National Library of Medicine. A study of potential disease modifying treatments in individuals at risk for or with a type of early onset AD caused by a genetic mutation (DIAN-TU). ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05552157 (2026)."},{"key":"4305_CR71","unstructured":"US Food and Drug Administration. Accelerated approval \u2013 expedited program for serious conditions guidance document. FDA https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/accelerated-approval-expedited-program-serious-conditions (2024)."},{"key":"4305_CR72","unstructured":"FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource. (Food and Drug Administration and National Institutes of Health, 2016)."},{"key":"4305_CR73","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1002\/alz.12754","volume":"19","author":"SE Schindler","year":"2023","unstructured":"Schindler, S. E. et al. Using Alzheimer\u2019s disease blood tests to accelerate clinical trial enrollment. Alzheimers Dement. 19, 1175\u20131183 (2023).","journal-title":"Alzheimers Dement."},{"key":"4305_CR74","doi-asserted-by":"crossref","unstructured":"Henkel, C., Seibert, S. & Nichols Widmann, C. Current advances in computerized cognitive assessment for mild cognitive impairment and dementia in older adults: a systematic review. Dement. Geriatr. Cogn. Disord. 54, 109\u2013119 (2024).","DOI":"10.1159\/000541627"},{"key":"4305_CR75","first-page":"24","volume":"2020","author":"AM Staffaroni","year":"2020","unstructured":"Staffaroni, A. M., Tsoy, E., Taylor, J., Boxer, A. L. & Possin, K. L. Digital cognitive assessments for dementia: digital assessments may enhance the efficiency of evaluations in neurology and other clinics. Pract. Neurol. 2020, 24\u201345 (2020).","journal-title":"Pract. Neurol."},{"key":"4305_CR76","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41746-025-01583-5","volume":"8","author":"SE Polk","year":"2025","unstructured":"Polk, S. E. et al. A scoping review of remote and unsupervised digital cognitive assessments in preclinical Alzheimer\u2019s disease. npj Digit. Med. 8, 266 (2025).","journal-title":"npj Digit. Med."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04305-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04305-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04305-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T14:02:56Z","timestamp":1776780176000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04305-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":76,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["4305"],"URL":"https:\/\/doi.org\/10.1038\/s41591-026-04305-w","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"26 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.P.M., L.C. and M.G.A. declare no competing interests. J.L.C. has provided consultation to Acadia, Acumen, ALZpath, AnnovisBio, Artery, Axsome, Biogen, Bristol Myers Squibb, Eisai, Fosun, GAP Foundation, Hummingbird Diagnostics, IGC, Janssen, Julius Clinical, Kinoxis, Lighthouse, Lilly, Lundbeck, LSP\/eqt, Merck, MoCA Cognition, Novo Nordisk, NSC Therapeutics, Optoceutics, Otsuka, ReMYND, Roche, Scottish Brain Sciences, Signant Health, Simcere, sinaptica and T-Neuro pharmaceutical, assessment, and investment companies. J.L.C. is supported by NIGMS grant P20GM109025; National Institute on Aging (NIA) grants R35AG71476 and R25AG083721-01; NINDS RO1NS139383; Alzheimer\u2019s Disease Drug Discovery Foundation (ADDF); Ted and Maria Quirk Endowment; and Joy Chambers-Grundy Endowment. S.M. serves on the board of directors of Senscio Systems and the scientific advisory boards of ALZpath and Boston Millennia Partners and has received consulting and\/or speaker fees from Biogen, C2N Diagnostics, Eisai, Eli Lilly, Novartis, Novo Nordisk and Genentech\/Roche. University of Southern California has research agreements, on which S.M. is principal investigator, with Biogen, C2N, Eli Lilly, Eisai and Roche\/Genentech. D.J.S. is a Director of Prothena Biosciences and an ad hoc consultant to Roche and Eisai. R.D. is a full-time employee of Axxium Life. N.M.-C. has received speaker\/consultancy fees from Biogen, Eli Lilly, Merck and Owkin. M.B. is an employee of Johnson & Johnson. D.S. is an employee of Vaxine Pty. N.P. is an employee of Vaxine Pty and inventor on patents relating to AD vaccines. R.C.M. is a principal investigator on NIA grant R01AG061091, receives consulting fees from Global Alzheimer\u2019s Platform Foundation, AgeneBio and Amyriad Therapeutics, serves on the Board of Governors for Alzheimer\u2019s Drug Discovery Foundation and the Board of Directors for Cogstate, and holds stock in Eli Lilly and Company. G.V. is the Convener of CEOi. B.T. is the Executive Director of CEOi. K.A.P. is a paid consultant for CEOi. E.M. is supported by funding from the NIA (K23AG046363, U01AG059798), the Anonymous Foundation, GHR, the Alzheimer\u2019s Association, and institutional support, and additional research support (to the institution) has been provided by Eli Lilly, Eisai, Hoffmann-La Roche and the DIAN-TU Pharma Consortium. E.M. has participated in speaker engagements for Eisai, Neurology Live and Projects in Knowledge-Kaplan, and advisory board roles, consulting and Data Safety Monitoring Board participation have included relationships with Eli Lilly, Alnylam, Alector, Alzamend, Sanofi, AstraZeneca, Hoffmann-La Roche, Grifols, Johnson and Johnson, Vigil Neuroscience and Merck. S.B.H. is the owner and an employee of Pentara Corporation, a consulting firm that provides services to more than 30 pharmaceutical, biotech, non-profit and academic organizations involved in clinical research, including neurodegenerative and other disease areas. R.A.S. has served as a consultant or on scientific advisory boards for AbbVie, AC Immune, Acumen, Alector, Apellis, Biohaven, Bristol Myers Squibb, Genentech, Ionis, Janssen, Oligomerix, Prothena, Roche and Vaxxinity over the past 3 years, has received research funding from Eisai and Eli Lilly for public\u2013private partnership clinical trials, and receives research grant funding from the NIA\/National Institutes of Health, GHR Foundation and the Alzheimer\u2019s Association.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}